Medicilon and Hailu Biotech of Yangtze River Pharmaceutical Group Forge Strategic Cooperation to Accelerate New Drug R&D and Global Outreach
On March 30, Medicilon held a strategic cooperation signing ceremony with Suzhou Hailu Biotech, a wholly-owned subsidiary of Yangtze River Pharmaceutical Group. The collaboration will focus on deepening synergy in preclinical new drug R&D, project introduction, and global market expansion, with the goal of jointly building an efficient, open, and international R&D ecosystem spanning from source […]
